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Abstract
Background—Risk factors for cardiovascular disease (CVD) not only increase the risk for
clinical CVD events, but also are associated with a cascade of neurophysiologic and
neuroanatomic changes that increase the risk of cognitive impairment and dementia. Although
epidemiological studies have shown that exercise and diet are associated with lower CVD risk and
reduced incidence of dementia, no randomized controlled trial (RCT) has examined the
independent effects of exercise and diet on neurocognitive function among individuals at risk for
dementia. The ENLIGHTEN trial is a RCT of patients with CVD risk factors who also are
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characterized by subjective cognitive complaints and objective evidence of neurocognitive
impairment without dementia (CIND)
Study Design—A 2 by 2 design will examine the independent and combined effects of diet and
exercise on neurocognition. 160 participants diagnosed with CIND will be randomly assigned to 6
months of aerobic exercise, the DASH diet, or a combination of both exercise and diet; a (control)
group will receive health education but otherwise will maintain their usual dietary and activity
habits. Participants will complete comprehensive assessments of neurocognitive functioning along
with biomarkers of CVD risk including measures of blood pressure, glucose, endothelial function,
and arterial stiffness.
Conclusion—The ENLIGHTEN trial will (a) evaluate the effectiveness of aerobic exercise and
the DASH diet in improving neurocognitive functioning in CIND patients with CVD risk factors;
(b) examine possible mechanisms by which exercise and diet improve neurocognition; and (c)
consider potential moderators of treatment, including subclinical CVD.
Keywords
Neurocognition; Cognitive impairment; Dementia; Aerobic exercise; Nutrition; DASH diet;
CIND; Randomized Clinical Trial
Introduction
It has been estimated that one in three Americans will experience a stroke, dementia, or both
during their lifetimes (1). As the world population ages, the number of older adults
developing dementia is estimated to increase from the current 26.6 million to over 106
million by mid-century (1-3) and many more will develop cognitive impairments without
meeting criteria for dementia (i.e., CIND), making neurocognitive disorders a national
priority (4). The term CIND was first used in the Canadian Study of Health and Aging (1)
for individuals whose difficulties with memory or other cognitive domains were not
sufficiently severe to meet the diagnostic criteria for dementia, but were judged to be distinct
from individuals with normal cognition. Amnestic mild cognitive impairment is generally
considered to represent a subset of CIND with distinct memory complaints, while CIND is a
broader category that often involves more subtle deficits in executive function, language
abilities, and other non-memory cognitive domains that represent the earliest signs of
dementia (5-7). Because substantive neuronal losses have already occurred by the time a
diagnosis of dementia is made, none of the medical therapies currently available are likely to
be able to replace or restore lost nerve cells. Thus, there is a great need to develop strategies
to halt or slow the earliest signs of dementia, i.e., CIND, before significant and irreversible
neuronal and functional losses have occurred.
It is now widely recognized that known risk factors for CVD, including hypertension,
diabetes, and hyperlipidemia, are risk factors not only for CVD events, but also for dementia
and late-life cognitive decline (8, 9). The ENLIGHTEN trial seeks to examine the impact of
diet and exercise, two lifestyle interventions known to reduce CVD risk, as potential
approaches to improve neurocognition in patients with CIND who are vulnerable to
developing dementia and progressive neurocognitive impairments.
Cardiovascular Disease and Cognitive Function
It is well established that strokes, lacunar infarcts, and carotid atherosclerosis can lead to
cognitive impairment and increase the risk for dementia(10-15), and recently developed
dementia risk profiles now include vascular risk factors(16). Neuropathological studies
indicate that the pathological changes associated with dementia frequently co-occur with
vascular pathology(17). The Rotterdam Study, for example, demonstrated that indices of
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atherosclerosis were associated with both vascular dementia (VaD) and Alzheimer's disease
(AD), and that the prevalence of both were associated with atherosclerotic disease (18-20).
Half of patients with CVD who develop dementia have AD and more than a third of
pathologically confirmed AD patients have evidence of vascular lesions (21). In addition,
cerebrovascular risk factor reduction using statins is known to decrease the risk of stroke
and may be associated with reduced risk of dementia (22). Furthermore, the effects of VaD
and AD pathologies are additive, and in most population-based samples these conditions co-
occur (23-25).
Prospective observations confirm that those individuals with subclinical CVD (determined
by intima media thickness [IMT], carotid stenosis, and EKG abnormalities) are more likely
to show cognitive decline over five years (26). Structural measures of atherosclerotic
burden, such as IMT, and functional measures of endothelial impairment are associated with
decrements in cognitive performance in cross-sectional studies (27-29) as well as with
cognitive decline in prospective examinations (30-32). It has been suggested that IMT may
represent a marker for CVD and generalized atherosclerosis rather than a cause of cognitive
impairment (33). Vascular endothelial function provides an important “barometer” of
atherosclerotic risk that plays a vital role in the development, progression and clinical
manifestations of atherosclerosis (34-37) and can be assessed non-invasively using vascular
ultrasound techniques to determine flow-mediated dilatation (FMD) of the brachial artery
(38). FMD represents an index that a) has been related to a wide range of CVD risk factors
(35, 39), b) is predictive of CVD events, including death, MI and stroke (40-43), and c) may
be improved both by pharmacological therapies and lifestyle interventions in patients with
CVD (44-46). Endothelial dysfunction also has been detected in patients with AD and VaD
(47) and is characteristic of dementia (48) and is related to neuropsychological deficits in
patients with depression (27) suggesting that endothelial dysfunction may be a common
etiologic pathway and biomarker for both disease processes.
Abnormalities in glucose metabolism are also associated with dementia (49-55) and elevated
levels of inflammatory markers such as C-reactive protein are associated with more rapid
cognitive decline (56), particularly in the presence of the metabolic syndrome (57), and are
prospectively related to cognitive impairment (58). Taken together, these is emerging
evidence that CVD risk factors are also risk factors for dementia, and that improving CVD
biomarkers may be effective in reducing the risk of neurocognitive impairment and
dementia (59).
Lifestyle Factors and Neurocognition
There is growing recognition that lifestyle factors may have important effects on both heart
and brain health. Chiuve et al. (60) studied over 114,000 men and women and observed that
body mass index < 25 kg/m2, > 30 min/day of moderate physical activity, not smoking or
drinking alcohol to excess, and scoring in the top 40% on a healthy diet score were key
elements to reduced stroke risk.
Observational studies have shown that physically active individuals perform better on
neurocognitive tests compared to their less active counterparts (61, 62). Results from
interventional studies also indicate that aerobic exercise is associated with improved
cognitive functioning, although the evidence is inconsistent(63-68)and studies often exclude
patients with cognitive impairments (65). We recently noted that individuals with
diminished cognitive abilities and CVD risk factors (i.e., vascular CIND) may achieve
greater neurocognitive benefits from lifestyle interventions compared to cognitively intact
individuals (69). Two recent studies of patients with cognitive impairment also are relevant:
In an Australian study, 170 patients with reported memory problems were randomized to 6
months of home-based physical activity or to an education control (70). Results revealed
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that participants in the physical activity group had better ADAS-cog scores compared to
those in the usual care control group and that the benefits were apparent after 6 months and
persisted for 12 months. Although these findings are promising, changes in aerobic fitness
were not measured, the exercise training program was not documented, and the mechanisms
by which exercise produced improvements in neurocognition were not assessed. In another
recent RCT of patients with cognitive impairment, Baker et al.(71) demonstrated that 6
months of high intensity aerobic exercise improved executive control processes, with effects
more pronounced for women compared to men. Women also showed greater improvements
in indices of glucoregulation and insulin sensitivity, suggesting that neurocognitive
improvements may be mediated by cardiovascular and metabolic effects of exercise.
However, the sample was small (N=33) and only a completers analysis was reported.
Although it has been suggested that exercise may reduce incident dementia by stimulating
growth factors and improving cerebrovascular risk factors, the mechanisms responsible for
improved neurocognition require further study (72).
The relationship between diet and cognition also has been a topic of increasing interest.
Recent studies have shown that variations in dietary practices and nutrient intake are
predictive of cognitive decline (73), dementia (74), and AD (75). A number of specific
nutrient components of these diets have been examined in relation to cognitive performance
including dietary fatty acids and fish oil (76-78), and various supplements such as vitamins
E and C (79-81), B6, B12 (82-84), and folate (85, 86). However, to date, virtually all RCTs
have focused on dietary supplements or nutrients, rather than a ‘whole diet’ approach, with
generally negative or inconsistent results (87). Recent observational studies have shown that
the Mediterranean diet is associated with reduced risk of neurocognitive impairment and
dementia, and that adherence to this diet may protect against subsequent cognitive
dysfunction in a dose-dependent fashion (88). Moreover, Scarmeas(89) recently
demonstrated that adherence to a Mediterranean-type diet and physical activity were
independently and additively associated with lower risk of developing AD.
The DASH diet is a similar diet that is part of current national recommendations for the
prevention and treatment of HTN (JNC-7) (90), which emphasizes low fat dairy products,
fruits and vegetables, and reduced fat and cholesterol (91). The DASH diet is effective in
reducing BP in all segments of the population and it is particularly effective in African
Americans, a group that is disproportionately affected by CVD and in whom dementia is
approximately twice as likely to develop compared to whites (92, 93). In a prospective
cohort study of 88,517 women nurses adherence to the DASH diet was associated with
lower risk of IHD and stroke (94). A subanalysis also found that the DASH diet was
associated with lower inflammatory markers associated with IHD. Because of the known
benefits of the DASH diet for improving CVD risk factors, independent of weight loss, we
propose to examine the impact of the DASH diet alone and combined with aerobic exercise,
on neurocognition in patients with CVD risk factors and CIND. Preliminary data from our
group have shown that the DASH diet is associated with improved neurocognition, and
when combined with exercise, the DASH diet may produce even greater beneficial effects
on vascular function and neurocognition (95).
Aims of the ENLIGHTEN Trial
The ENLIGHTEN Trial is a single-site, RCT sponsored by the National Heart, Lung, and
Blood Institute examining the effects of aerobic exercise and the DASH diet on biomarkers
of CVD risk and neurocognitive function among adults with vascular CIND. We will
examine the following hypotheses:
a. Aerobic exercise and the DASH diet independently will be associated with greater
improvements in neurocognitive functioning compared to controls; the effects will
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be additive, with greatest improvements observed in the combined diet and exercise
group; (b) Aerobic exercise and the DASH diet independently will be associated
with greater improvements in CVD risk factors including (i) BP and vascular
stiffness; (ii) Framingham Stroke scores; (iii) subclinical atherosclerosis as assessed
by measures of flow mediated dilation (FMD); (iv) inflammation assessed by C-
reactive protein; and (v) glucose metabolism and insulin resistance; and (3)
improvements in vascular function will mediate the relationship between exercise
and diet and improved neurocognition.
Research Design and Methods
One hundred sixty men and women with either CVD or two or more risk factors for CVD
who meet eligibility criteria will be randomized to one of four groups for the 26-week
intervention to include (a) supervised aerobic exercise, (b) DASH diet, (c) combined
supervised exercise and DASH diet, or (d) a health education control group. The study
design is depicted in Figure 2. Persons complete written informed consent, are initially
screened for CIND and history of CVD or CVD risk factors and, if eligible, undergo a
physical examination by the study physician to determine eligibility and safety of
participation. Upon completion of the medical and cognitive screening, eligible participants
undergo an assessment of cognitive function and cardiovascular biomarkers at baseline and
again after 6 months of treatment; patients also undergo another cognitive assessment 18
months after baseline assessment (12 months posttreatment) by an examiner blind to patient
group and baseline ratings. Our protocol was approved by the National Institutes of Mental
Health and by the Institutional Review Board at Duke University Medical Center.
Participant eligibility
The following eligibility criteria will allow patients to enter the baseline evaluation phase of
the trial: (a) Male or female outpatients ≥ 55 years of age with at least two traditional CVD
risk factors or prior CVD event (myocardial infarction, coronary artery bypass grafting
[CABG], >70% stenosis, peripheral vascular disease, or mild stroke without residual
deficits), (b) subjective complaints about cognitive abilities [e.g. reduced memory], (c)
capacity to give informed consent and follow study procedures, (d) adequate visual and
auditory acuity to allow valid neuropsychological testing, (e) and a score between 20 and 25
on the Montreal Cognitive Assessment (MoCA)(96) or letter fluency ≤ 13 or animal fluency
≤ 15(97) and a score >0.5 on the Activities of Daily Living questionnaire from the
Alzheimer's Disease Cooperative Study (ADCS). All participants (and study partners) will
provide written informed consent prior to the screening. In general, CIND patients are able
to provide consent for themselves. If there is a question regarding capacity to consent, we
also obtain consent for the patient from the patient's designee (power of attorney or
designated responsible family member). Consent also will also be obtained from the study
partner for their participation in the study (i.e. for their role in completing questionnaires,
accompanying patients to their treatment sessions).
Interventions
Following completion of the baseline assessments, patients will be randomly assigned to (1)
Aerobic Exercise (AE) training; (2) the DASH diet; (3) a combination of AE and DASH; or
(4) Health Education controls. All conditions will consist of 3 months of face-to-face contact
followed by 3 months of home-based treatment. Assignment of patients will proceed using a
conditional random assignment plan, with assignment conditional upon gender, age (55-69
or ≥70 yrs) severity of CIND (MoCA scores 20-23 or ≥ 24), and history of CVD event
(presence or absence).
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Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will
exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or
at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined
at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up
exercises followed by 30 minutes of continuous walking or (stationary) biking. Each
exercise session will conclude with a 10 minute period of cool-down exercises. During
weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3
aerobic sessions per week at home at 60-70% HRR. We have used home-based exercise in
our prior work of older depressed patients(98) and in the HF-ACTION trial(99), in which
patients also were transitioned to home-based exercise after 3 months of supervised exercise.
Participants in the AE alone condition will not receive any counseling in the DASH diet and
will be encouraged to follow their usual diets.
Dietary Approaches to Stop Hypertension (DASH) Diet
Participants in the DASH condition only receive instruction in modifying the content of their
diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to
focus their attention on what they eat. Participants will have been told (in the initial consent
form) that the study is designed to study effects of two interventions (altering diet content
and exercise) both of which have been shown to improve health. Participants will also be
told that it may be easier or more effective for them if they focus first on learning to alter
diet content, and they are free to exercise at the end of the 6-month period. Strategies to
improve motivation will be used to enhance commitment and confidence for behavior
change and to help participants explore and resolve ambivalence (100, 101).
Combined aerobic exercise and DASH diet
Participants in the AE + DASH condition will receive both the Exercise and DASH
interventions as described above. This approach of combining treatments has been used
successfully in our prior work in which we combined AE and diet (45)in hypertensive
adults.
Health education control group
The Health Education control group will receive weekly 15-min lectures on relevant, health-
related topics but will not receive instruction in the DASH diet nor will exercise be
promoted. These participants will be asked to maintain their usual dietary and exercise
habits for 6 months until they are re-evaluated. Each weekly session will address a topic
relevant for CIND such as medical and psychosocial aspects of aging, medication use, CVD
risk factors, and symptom management. The health educator will follow an outline for each
session, and will encourage patients (and their study partners) to ask questions. These
sessions are designed to provide useful information about medical aspects of CVD, but will
not provide instruction in the DASH diet or exercise. Thus, this control condition will help
to minimize the possibility that gains result merely from staff attention or from the active
involvement of the study partner in the treatment.
Participant adherence
Supervising exercise physiologists document exercisers' attendance at each exercise session
as well as the modality used during training (i.e., walking on a treadmill, stationary bicycle,
etc.). In addition, they record exercisers' heart rate ranges during training and ratings of
perceived exertion three times during the exercise session. Participants in both the DASH
and combined groups will have their weekly dietary intake recorded and examined by a
study dietician. All participants complete a monthly tracking form that inquires about
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changes in health status, medication use, or lifestyle habits (e.g., diet, exercise, etc.). This
procedure is designed to determine the occurrence of ‘unplanned crossover’, e.g., control
participants who initiate lifestyle changes or DASH only participants who begin exercising.
Participant safety
The ENLIGHTEN study will take special precautions to ensure patient safety. Our study
neurologist will work closely with the study primary investigator and study psychiatrist on
all aspects of patient safety. First, patients will be carefully evaluated. Follow-up data will
be reviewed at regular monthly consensus conferences attended by the clinical staff
including the study psychiatrist and neuropsychologist. Significant clinical deterioration will
be defined as meeting any of the following conditions: 1) change in CDR from 0.5 to higher
score, clinician or informant report of significant worsening; 2) noncompliance with
protocol; 3) emergence of significant psychopathology such as depression or agitation that
interferes with the conduct of study or subject safety; 4) new onset medical or neurological
problems such as stroke or Parkinson's disease.
Second, we recognize that depression is likely to be present in a subgroup of participants
(i.e., vascular depression) and depressive symptoms will be carefully monitored. Any patient
who becomes actively suicidal will be dropped from further participation and referred for
treatment. Our study coordinator will contact the patient within 72 hours after the referral to
ensure that the patient has followed through with the referral. Patients who voluntarily drop
out of treatment, or who are unable to complete our protocol will not be replaced, but will be
contacted for follow-up assessment. Although we do not anticipate a differential pattern of
treatment dropout, our sample size is adequate in the event of differential dropouts. In order
to ensure patient safety, the coordinator will also contact patients by telephone at regular
intervals throughout the follow-up period.
Third, exercise progression will be gradual, with careful attention to clinical symptoms.
Because injury resulting from exercise is an important deterrent to continuing an exercise
program, patients will be carefully monitored and the exercise prescription of frequency,
intensity and duration will be strictly adhered to(102).
Assessment of intermediate endpoints
In this study, we will examine changes in important biomarkers of risk (i.e., ‘intermediate
endpoints’) in ‘vulnerable’ patients with either CVD or risk factors for CVD, as well as
CIND. The concept of looking at markers of ‘vulnerable plaque’ (e.g., endothelial
dysfunction), ‘vulnerable (thrombogenic) blood’ (e.g., markers inflammation), and
‘vulnerable vasculature’ (e.g., CVD risk factors, such as blood pressure) in combination to
identify the ‘vulnerable patient’ has been advanced by a panel of prominent cardiovascular
scientists (103, 104). We assess changes in CVD risk factors, (blood pressure and lipids),
flow mediated dilation (FMD), markers of inflammation (C-reactive protein and
interleukin-6) before and after treatment. These intermediate endpoints tap key dimensions
of the ‘vulnerable patient’ (2,3) and were selected because of: (a) their association with
neurocognitive function; (b) their association with adverse cerebrovascular outcomes; and
(c) their potential to be modified by treatment, including exercise and/or the DASH diet.
Neurocognitive Function
While CIND involves a wide range of cognitive deficits that may involve many domains,
there is likely to be an impairment in “executive functions” such as slowed information
processing, impaired ability to shift attentional sets, and deficits in the ability to hold and
manipulate information (i.e., working memory) (Garrett et al., 2004; V. Hachinski et al.,
2006; Nyenhuis et al., 2004). We adopted a 45-60 minute neuropsychological battery as
Blumenthal et al. Page 7













recommended by the Neuropsychological Working Group for vascular cognitive
disorders(105). Assessments will include tests of Executive/Attention (Digit Symbol, Trail
Making Test, Stroop Test, Ruff 2 & 7 Test, Animal Naming, Digit Span), Visuospatial
ability (Rey-O), Language/lexical Retrieval (Boston Naming test; Animal Naming,
Controlled Oral Word Association Test), and Memory/Learning (HVLT-R, Rey-O,
immediate & delayed recall). The neuropsychological test battery will be administered in a
fixed order with alternative forms, in counterbalanced order, to minimize practice effects.
The tasks are streamlined with standard discontinuation rules applied to reduce subject
frustration and overall burden.
Markers of CVD risk
1) Blood Pressure—Clinic BP will be assessed by a trained research assistant (blinded to
treatment), using the auscultatory method, with a calibrated sphygmomanometer and
stethoscope.
2) Framingham Stroke Risk Profile (FSRP)—A modified version of the Framingham
Stroke Risk Profile (106, 107), a risk assessment tool used to assess the risk of incident
stroke, will be used an index of cerebrovascular risk, including SBP, antihypertensive
medications, diabetes mellitus, cigarette smoking, CVD, left ventricular hypertrophy, and
atrial fibrillation.
3) Glucose and lipids—Glucose and lipids will be obtained from fasting blood samples.
Markers of vascular health
1) Brachial Artery Flow-Mediated Dilation (FMD)—Our technique for assessing FMD
follows procedures first described by Celermajer and colleagues(35) and conforms to current
standards established by ACC committee guidelines(38).
2) Arterial stiffness—Pulse wave velocity (PWV), measured using the Complior device
(Artech Medical, Pantin, France), will be used as an index of central artery stiffness (108).
3) Carotid Artery Intima-Media Thickness (IMT)—Carotid artery IMT will be
assessed by high-resolution B-mode ultrasound imaging of the common carotid arteries.
Measures of chronic inflammation
Plasma inflammatory biomarkers will be measured by ELISA using commercially available
kits. Cytokines will be measured using in vitro enzyme-linked immunosorbent assay
(ELISA). Due to its association with neurocognitive functioning (57) and with several CVD
risk factors(109), we will examine C-Reactive Protein (CRP) via high-sensitivity kits
obtained from American Diagnostica, Inc. (Stamford, CT).
Primary and secondary endpoints—The effect of treatment on the primary endpoint
of Executive function will be examined using the generalized linear model in the R software
package (http://r-project.org). We will adopt the approach recommended by O'Brien(110),
constructing a rank-summed composite variable to represent the executive function
endpoint. The components of the executive function composite will be the Digit Symbol,
Trail Making Test, Stroop Test, Ruff 2 & 7 Test, Digit Span, and Animal Naming measures.
The composite approach has advantages over testing multiple individual endpoints,
including increased reliability, enhanced precision of the treatment estimate, improved
power, and minimization of Type I Error (111, 112). The 6-month composite will serve as
the response variable. The predictor variables will be specified a priori, with the Exercise
Blumenthal et al. Page 8













and DASH interventions as two-level factors, and age, gender, ethnicity, education, MoCA
score at baseline, and the pretreatment level of the executive function composite as
adjustment covariables. Although we predict that the effect of the two treatments will be
additive, we will also examine the Exercise by DASH interaction. If a significant treatment
effect is observed for the composite, we will follow up with an examination of the individual
neurocognitive tests used to create the composite, with a correction for multiplicity (113).
The secondary 6-month endpoints of the additional neurocognitive measures and biomarkers
of risk variables (BP, vascular stiffness, Framingham score, FMD, inflammation, lipids,
glucose metabolism and insulin resistance) will be evaluated using generalized linear models
in parallel fashion to those evaluating neurocognition. Similarly, we will use the generalized
linear model for the measures of quality of life and lifestyle factors (diet and physical
activity) and aerobic fitness. Separate models will be estimated for each of these secondary
outcomes (with the appropriate composites for the neurocognitive measures), again
correcting for multiple testing.
Exploratory analyses—We will examine treatment-related improvements in longer term
(i.e., 18-month) neurocognitive functioning, including the transition from CIND to
dementia, and quality of life using generalized mixed models, with the 6- and 18-month
neurocognitive composites as repeated measures response variables. These models will
include the treatment indicators and the aforementioned adjustment covariates. Mediational
analyses will proceed using the procedures outlined by Kenny and MacKinnon(114, 115).
Formal tests of mediation will be conducted using the indirect effect approach with
bootstrapped confidence intervals suggested by Mackinnon(115). Moderator analyses will
explore the extent to which the treatment might be differentially effective across
subpopulations, adjusting for pretreatment levels of age, ethnicity, baseline neurocognitive
function, education, and Framingham Stroke Risk scores. For example, neurocognitive
impairment has been shown to predict mortality in men but not in women, and stroke and
diabetes predicted mortality independent of neurocognition in women, but not in men (116).
In addition, physical activity has been shown to be associated with lower risk of CIND in
women, but not in men(117). Therefore, we will consider gender as a potential moderator in
our analyses. The etiology of dementia is complex and is not fully understood, but both
genetic and environmental factors are involved(118). While evidence suggests that genetic
factors are important risk factors for dementia, genes do not account for all the variance in
disease expression(119). Our own work in a population cohort of exceptionally long-lived
individuals known as the Cache County Memory Study(120) suggests that AD is not an
inevitable consequence of age or of the APOE genotype and that nearly 30% of the
population did not develop AD regardless of their APOE genotype. Converging evidence
supports the view that lifestyle and environmental factors contribute to symptom onset(8, 9)
and that genetic factors may also moderate the effects of diet and exercise on
neurocognition. We also are interested in whether patients with greater subclinical vascular
disease will be differentially responsive to treatment. While this is admittedly an exploratory
aspect of our application, pilot data from our laboratory suggest that patients with greater
underlying vascular disease (assessed by IMT) could potentially benefit most from diet and
exercise(95). The results of these subsample/moderator analyses will be interpreted strictly
as exploratory and used to guide further research.
Power Analysis—The effects of primary interest are the main effects for exercise and the
DASH diet on the executive function composite at 6 months. Our power estimates are based
on the following assumptions: 1) pre-treatment level of the composite, age, gender, and
ethnicity as covariates in the model; 2) correlation of 0.4 between the covariates and the
outcome; 3) an initial sample size of 160 patients with 20% attrition at 6 months (i.e., about
32 patients with complete data in each of the 4 cells); 4) an alpha of 0.05. For a given main
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effect, our sample size will yield a power of about .80 to detect a treatment effect of about .
48 standard deviations, and .90 for an effect of about 0.53 standard deviations. In
unpublished analyses of our ENCORE study data support the feasibility of observing effects
sizes in this range. Among participants in the lowest tertile of executive function before
entering treatment, we observed effects sizes of 0.80 for the combined DASH and exercise/
weight management group (compared to usual care), and over 0.50 for the DASH alone
group on a composite of executive function measures. We note that these power estimates
are likely to be conservative in that we have used a low correlation estimate between the
adjustment covariates and the outcome, and also have not accounted for the additional
power that is obtained with methods for imputing missing data(121).
Discussion
The ENLIGHTEN study has several important innovations in comparison with previous
trials. ENLIGHTEN is the first randomized trial to examine the effects of diet and exercise
among patients with CIND, a vulnerable patient group known to be at risk for VaD and AD.
Our inclusion criteria are novel in that we are identifying patients both by the presence of ≥
2 cerebrovascular risk factors as well as poor performance on brief cognitive screening
measures(97). Because cognitive deficits in CIND are often heterogeneous we feel that
using this multi-method identification method provides the most appropriate identification
method to capture a generalizable study sample, particularly because the MoCA was
designed to identify MCI(96). In addition, our study will utilize a comprehensive
neurocognitive assessment battery, recommended by a recent consensus statement (105).
The ENLIGHTEN study will collect data on intermediate CVD endpoints for a variety of
reasons. Because ‘hard’ neurological end-points, such as dementia, occur relatively
infrequently even in clinical populations, it is very difficult for any intervention trial to have
adequate power to examine these outcomes. However, we will be collecting sensitive
neurocognitive data that has previously been recommended by experts in the field of
neurology for the detection of cognitive impairment with a vascular etiology (105). In
addition, as we have outlined above, we will collect several measures of CVD risk and
vascular health which have been shown to be sensitive to the effects of exercise (45) and are
predictive of neurological outcomes (122). In the present study, we will examine changes
vascular function as potential mediators of treatment improvements in neurocognitive
function. Because vascular function has been shown to be associated with worse
neurocognitive prognosis (30) and is modifiable with treatment, we feel that these data
provide ideal intermediate endpoints to assess the impact of our intervention on
hypothesized mediators of cognitive function. Because experts have advocated a
comprehensive assessment of vulnerable patients (103, 104) we will assess other
intermediate endpoints including inflammation, insulin sensitivity, and lipids.
Conclusions
There is now ample evidence that CVD risk factors are associated with increased risk of
cognitive impairment and dementia in later life, and that lifestyle factors such as diet and
exercise exert a protective effect on cognitive function. However, no randomized trials have
examined the effects of a combined exercise and dietary intervention on cognitive function
among individuals vulnerable to dementia. The ENLIGHTEN study is designed to assess the
effects of the DASH diet and aerobic exercise, both independently and in combination, on
cognitive function. The study will collect sensitive and clinically validated measures of
cognitive function in order to provide a comprehensive assessment of cognition both before
and after treatment. The ENLIGHTEN study will also collect sensitive measures of vascular
function in order to assess whether improving vascular health may improve cognitive
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outcomes. Finally, we will conduct a follow-up assessment one year after completion of the
intervention to examine intervention effects on conversion to dementia. The ENLIGHTEN
study promises to provide important information about the value of exercise and the DASH
diet in improving cognitive function among individuals with CIND, and will provide
insights into the mechanisms by which these interventions may reduce the risk for
subsequent development of dementia.
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illustrates how aerobic exercise and diet may enhance neurocognitive function by reducing
CVD risk factors. This model is consistent with the notion that a healthy vascular system
maximizes the brain's overall functioning and cognitive reserve. Compromised blood flow
due to atherosclerosis, vascular stiffening, or endothelial dysfunction may lead to reduced
cerebral perfusion and ineffective clearance of waste. Regardless of whether the relation is
due to shared risk factors or to direct and indirect influences of CVD on brain pathology,
exercise and dietary interventions designed to reduce CVD risk factors are plausible
strategies to prevent, slow, or even reverse cognitive decline in vulnerable patients with
CVD risk factors and CIND.
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illustrates the timeline of study assessments and interventions. Using a 2 × 2 design,
participants will be randomized to receive aerobic exercise, the DASH diet, a combined
exercise and DASH diet intervention, or a health education control group for six months.
Assessments of cognitive function and CVD risk factors will be conducted at baseline,
following six months of intervention, and again one year following completion of the
intervention.
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